Shanghai Labway Clinical Laboratory Co Ltd - Asset Resilience Ratio
Shanghai Labway Clinical Laboratory Co Ltd (301060) has an Asset Resilience Ratio of 2.10% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Shanghai Labway Clinical Laboratory Co L to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2021)
This chart shows how Shanghai Labway Clinical Laboratory Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 301060 current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Labway Clinical Laboratory Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Shanghai Labway Clinical Laboratory Co L for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥54.95 Million | 2.1% |
| Total Liquid Assets | CN¥54.95 Million | 2.10% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Labway Clinical Laboratory Co Ltd maintains only 2.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Labway Clinical Laboratory Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Labway Clinical Laboratory Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
LONZA GROUP UNSP.ADR 1/10
F:LO3A |
Diagnostics & Research | 3.04% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 13.42% |
|
Gencurix Inc
KQ:229000 |
Diagnostics & Research | 4.01% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Shanghai Labway Clinical Laboratory Co Ltd (2019–2021)
The table below shows the annual Asset Resilience Ratio data for Shanghai Labway Clinical Laboratory Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 19.99% | CN¥420.93 Million ≈ $61.60 Million |
CN¥2.11 Billion ≈ $308.10 Million |
+11.79pp |
| 2020-12-31 | 8.20% | CN¥120.63 Million ≈ $17.65 Million |
CN¥1.47 Billion ≈ $215.33 Million |
-8.07pp |
| 2019-12-31 | 16.27% | CN¥227.65 Million ≈ $33.31 Million |
CN¥1.40 Billion ≈ $204.72 Million |
-- |
About Shanghai Labway Clinical Laboratory Co Ltd
Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of in-vitro diagnostic products in China. The company distributes in-vitro diagnostic instruments, reagents, and related accessories and consumables. It also provides third-party medical testing, pathological diagnosis services, precision medicine, CRO, and sample bank laboratory services; scientific research technology and testing… Read more